The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.

导出 OA

翻译打印收藏纠错

作者： Guy,Brusselle ^[1] ; David,Price ^[2] ; Kevin,Gruffydd-Jones ^[3] ; Marc,Miravitlles ^[4] ; Dorothy L,Keininger ^[5] ; Rebecca,Stewart ^[6] ; Michael,Baldwin ^[7] ; Rupert C,Jones ^[8]

作者单位： Department of Respiratory Medicine, University Hospital Ghent, Ghent, Belgium ; Department of Epidemiology, Erasmus Medical Center, Rotterdam, Netherlands ; Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, Netherlands. ^[1] Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK ; Research in Real Life (RiRL), Singapore. ^[2] Box Surgery, Wiltshire, UK. ^[3] Pneumology Department, Hospital Universitari Vall d'Hebron, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain. ^[4] Novartis Pharma AG, Basel, Switzerland. ^[5] Research in Real Life (RiRL), Singapore. ^[6] Novartis Pharmaceuticals Limited, Horsham, UK. ^[7] Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK. ^[8]

关键词 GOLD guidelines chronic obstructive pulmonary disease observational study prescribing patterns primary care